From the 67th annual scientific sessions of the American Diabetes Association: Nebivolol demonstrates neutral effect on glucose levels
Nebivolol, an investigational (NDA submitted) vasodilating beta-blocker, demonstrated a neutral effect on blood glucose levels in two 12-week clinical studies of patients with hypertension.
Key Points
Nebivolol, an investigational (NDA submitted) vasodilating beta-blocker, demonstrated a neutral effect on blood glucose levels in two 12-week clinical studies of patients with hypertension, said George Bakris, MD, director, Hypertension Center, University of Chicago Medical Center, Illinois. The results of these trials were presented at the 67th Annual Scientific Sessions of the American Diabetes Association.
Preservation of glycemic control has been observed with carvedilol. "In the published studies and the studies we've done, nebivolol looks like it has a profile similar to carvedilol," Dr Bakris said. "Carvedilol, however, has been shown to improve insulin resistance, which has not yet been shown with nebivolol."
The trials of nebivolol were randomized, multicenter, placebo-controlled studies that included a total of 1,494 patients with stage 1 or stage 2 hypertension. One study included 825 patients who received nebivolol monotherapy. A second study of nebivolol as add-on therapy included 669 patients.
In the monotherapy study, patients randomized to nebivolol had a dosage-dependent increase in mean blood glucose levels of 0.8 to 7.2 mg/dL, which was not significantly different from the 7.1-mg/dL increase observed in patients randomized to placebo. The differences from baseline in both groups were nonsignificant.
In the add-on study, patients randomized to nebivolol had a mean increase of 0.7 mg/dL (20 mg/d) to 1.9 mg/dL (5 mg/d) in blood glucose levels compared with patients randomized to placebo, who experienced a mean increase of 2.6 mg/dL in blood glucose levels.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
